Summary by Futu AI
Vivos Therapeutics, Inc., a medical technology company, has entered into a material definitive agreement with an institutional investor, as reported in a Form 8-K filed with the SEC on February 15, 2024. The agreement, initially established on October 30, 2023, involved a private placement where Vivos Therapeutics sold approximately $4.0 million of securities, including common stock and Series A and B Common Stock Purchase Warrants. The Series B Warrants, with an exercise price of $3.83 per share, were fully exercised by the investor on February 14, 2024, for $4.02 per share, resulting in $4.0 million in gross proceeds for the company. In conjunction with this exercise, Vivos Therapeutics agreed to issue new Series B-1 and B-2 Common Stock Purchase Warrants as part of an inducement transaction. A.G.P./Alliance...Show More